Culture Biosciences

-34%

est. 2Y upside i

HealthcareSeries C

We grow cells for biotech companies.

Rank

#3531

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Culture Biosciences offers high growth but significant risk.

Last updated: July 3, 2026

Bull (20%)+85%

If IPO window opens and category leadership drives multiple expansion to ~40x, exit value ~$410M. Even after 20% dilution, upside ~85%.

Base (35%)-17%

Multiple converges to ~20x, exit value ~$205M, minimal upside. Dilution and preference stack erode returns.

Bear (45%)-100%

Multiple compresses to 10x, exit value ~$103M below total funding preference, common stock returns -100%.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

54%

Total funding of $107M represents 53.5% of estimated valuation, giving preference holders significant overhang.

Dilution Risk

high

Given limited runway and high burn, a new raise likely within 24 months, diluting common equity by ~20%.

Secondary Liquidity

none

No secondary market activity reported.

Other — 5 roles

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Culture Biosciences's data — designed to show you've done your homework.

1
“How does Culture plan to differentiate from large incumbents like Sartorius and Thermo Fisher?”
2
“What is the path to profitability given the high capital intensity?”
3
“What is the expected timeline for an exit (IPO or acquisition)?”

Our model estimates -34% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.